Clinical Trial: MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer

U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07894458) titled 'MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer' on Oct. 19.

Brief Summary: This study is a prospective single-arm clinical trial targeting patients with stage IB-IIIA non-small cell lung cancer (NSCLC) who have received neoadjuvant immunotherapy. The primary objective is to evaluate whether a personalized follow-up and adjuvant treatment strategy-based on the combination of ctDNA-based minimal residual disease (MRD) testing and pathological response-can effectively improve the 2-year postoperative recurrence-free survival (RFS). The study will enroll 100 patients scheduled for radical surgery...